To　formulate　a　novel　histological　typing　and　grading-rated　system　for　colorectal　cancer　(CRC)　for　evaluating　the　biological　behavior　of　CRC　and　prognosis.According　to　the　highly　heterogeneous　histological　features,　WHO　classification　and　histological　differentiation　criteria,　and　other　biological　behavior　parameters　of　CRC,　a　novel　histological　typing　and　grading-scale　system　for　CRC　was　designed.　The　histological　typing　and　corresponding　grading-scale　of　CRC　was　defined　as　the　following:　(1)　No　mucin-producing　adenocarcinoma,　including　tubular　adenocarcinoma,　sieve-like　acne　adenocarcinoma,　medullary　carcinoma,　serrated　adenocarcinoma　and　micropapillary　carcinoma,　etc.　(1-3　points);　(2)　Mucin-producing　adenocarcinoma,　including　mucinous　adenocarcinoma　and　signet　ring　cell　carcinoma　(3-4　points);　(3)　Squamous　cell　carcinoma　(1-3　points);　(4)　Neuroendocrine　tumors,　including　neuroendocrine　tumors,　neuroendocrine　carcinoma　(1-4　points);　(5)　The　special　type　of　CRC,　including　clear　cell　carcinoma,　spindle　cell　carcinoma,　etc.　(4-points);　(6)　Undifferentiated　carcinoma　(5　points).　The　pathology　report　form　was　formatted　based　on　the　major　histological　type　with　the　secondary　histological　type.　The　final　total　score　of　CRC　was　defined　as　the　sum　of　the　corresponding　grading　scores　for　different　histological　types.　The　total　score　of　a　single-structure　CRC　was　defined　as　the　corresponding　grading　score　multiplied　by　2.　A　total　of　666　patients　with　advanced　CRC　were　pathologically　reviewed　and　analyzed　to　assess　the　correlation　of　the　histological　typing　and　grading　scores　with　TNM　staging　and　lymph　node　metastasis.The　results　showed　a　significant　correlation　of　the　histological　grading-scale　and　TNM　staging　and　lymph　node　metastasis　(P＜0.05).　The　scores　of　CRC　histological　grading-scale　increased　synchronously　with　the　TNM　staging　and　lymph　node　metastasis　rate.The　novel　histological　grading　system　allows　objective　evaluation　of　the　biological　behaviors　and　prognosis　of　CRC　for　determining　individualized　postoperative　treatment.　This　system　still　needs　further　revision　and　updates　based　on　evidence　from　prospective,　multi-centered,　large-scale　trials.